- Hans Scientific™ is investing $2 billion to expand U.S.-based pharmaceutical manufacturing, including seven new facilities, with one injectable and lyophilization plant already operational.
- The investment is positioned to take advantage of new U.S. tariffs on imported pharmaceuticals and support reshoring of drug production.
Hans Scientific™, a Michigan-based pharmaceutical contract manufacturer, has announced a $2 billion investment in new U.S. manufacturing infrastructure. The expansion includes seven planned plants, with an injectable and lyophilization facility already completed, as the company aims to onshore drug production in response to new U.S. tariffs on imported pharmaceuticals.
The tariffs, announced by President Trump, impose 100% duties on branded pharmaceuticals, incentivising domestic production and aiming to reduce reliance on European supply chains. According to founder Manoj Bhargava, the move changes the cost equation for drug manufacturing: “Most drugs consumed in the U.S. are made in Europe—not because it’s more efficient, but because of taxes,” he said.
Hans Scientific highlights its capability to design, fabricate, and build its own facilities as giving it a speed advantage over competitors. The company aims to help pharmaceutical firms avoid tariff pressures and strengthen domestic supply chains while creating high-paying jobs in the U.S.
Bhargava emphasised the broader economic benefit of reshoring pharmaceutical production, noting that it keeps tax revenue at home and represents a “win-win” for the U.S. economy. Analysts also see the tariffs as part of a wider trend of reshoring critical industries for both economic and national security reasons.
The company’s six remaining plants are under construction, positioning Hans Scientific to meet anticipated growth in demand for U.S.-based drug manufacturing and provide turnkey contract manufacturing solutions for pharmaceutical firms.
